Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Executive Chairman

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593; and license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabet...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-05	Premium	back to issuer	Premium	Premium	Premium	-
2024-02-27	Premium	acquired	Premium	Premium	Premium	-
2022-11-29	Premium	bought	Premium	Premium	Premium	-
2022-11-28	Premium	bought	Premium	Premium	Premium	-
2021-12-20	Premium	sold	Premium	Premium	Premium	-
2021-02-26	Premium	bought	Premium	Premium	Premium	-
2021-02-26	Premium	bought	Premium	Premium	Premium	-
2021-02-26	Premium	bought	Premium	Premium	Premium	-
2020-12-17	Premium	bought	Premium	Premium	Premium	-
2020-12-10	Premium	bought	Premium	Premium	Premium	-
2020-11-24	Premium	bought	Premium	Premium	Premium	-
2020-05-15	Premium	bought	Premium	Premium	Premium	-
2020-05-12	Premium	bought	Premium	Premium	Premium	-
2020-03-10	Premium	acquired	Premium	Premium	Premium	-
2020-02-25	Premium	bought	Premium	Premium	Premium	-
2020-01-28	Premium	bought	Premium	Premium	Premium	-
2020-01-07	Premium	bought	Premium	Premium	Premium	-
2019-12-18	Premium	bought	Premium	Premium	Premium	-
2019-11-26	Premium	bought	Premium	Premium	Premium	-
2019-11-12	Premium	bought	Premium	Premium	Premium	-
2019-10-24	Premium	bought	Premium	Premium	Premium	-
2019-09-27	Premium	bought	Premium	Premium	Premium	-
2019-09-18	Premium	bought	Premium	Premium	Premium	-
2019-09-13	Premium	bought	Premium	Premium	Premium	-
2019-09-11	Premium	bought	Premium	Premium	Premium	-

VTVT - vTv Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for VTVT